argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024
argenx (Euronext & Nasdaq: ARGX), a global immunology company, has announced it will host a conference call and audio webcast on Thursday, October 31, 2024 at 1:30 PM CET (8:30 AM ET) to discuss its third quarter 2024 financial results and provide a business update. The webcast will be accessible through the Investors section of argenx's website, with a replay available for approximately one year. The company has provided international dial-in numbers for Belgium, France, Netherlands, United Kingdom, United States, Japan, and Switzerland.
argenx (Euronext e Nasdaq: ARGX), un'azienda globale nel campo dell'immunologia, ha annunciato che ospiterà una conferenza telefonica e un webcast audio giovedì 31 ottobre 2024 alle 13:30 CET (8:30 EST) per discutere dei risultati finanziari del terzo trimestre 2024 e fornire un aggiornamento sull'attività. Il webcast sarà accessibile attraverso la sezione Investitori del sito web di argenx, con una registrazione disponibile per circa un anno. L'azienda ha fornito numeri di accesso internazionali per Belgio, Francia, Paesi Bassi, Regno Unito, Stati Uniti, Giappone e Svizzera.
argenx (Euronext y Nasdaq: ARGX), una empresa global de inmunología, ha anunciado que llevará a cabo una conferencia telefónica y una transmisión de audio el jueves, 31 de octubre de 2024 a la 1:30 PM CET (8:30 AM ET) para discutir sus resultados financieros del tercer trimestre de 2024 y proporcionar una actualización empresarial. La transmisión estará disponible a través de la sección de Inversores en el sitio web de argenx, con una repetición accesible durante aproximadamente un año. La empresa ha proporcionado números de marcación internacional para Bélgica, Francia, Países Bajos, Reino Unido, Estados Unidos, Japón y Suiza.
argenx (Euronext 및 Nasdaq: ARGX)는 글로벌 면역학 회사로, 2024년 10월 31일 목요일 오후 1시 30분 CET(동부 표준시 기준 오전 8시 30분)에 세 번째 분기 2024년 재무 실적과 비즈니스 업데이트를 논의하기 위한 컨퍼런스 콜과 오디오 웹 캐스트를 진행한다고 발표했습니다. 웹 캐스트는 argenx 웹사이트의 투자자 섹션을 통해 접근 가능하며, 약 1년 동안 다시 보기 기능이 제공됩니다. 이 회사는 벨기에, 프랑스, 네덜란드, 영국, 미국, 일본 및 스위스의 국제 다이얼 인 번호를 제공했습니다.
argenx (Euronext et Nasdaq: ARGX), une entreprise mondiale en immunologie, a annoncé qu'elle tiendra un appel conférence et un webcast audio le jeudi 31 octobre 2024 à 13h30 CET (8h30 EST) pour discuter de ses résultats financiers du troisième trimestre 2024 et fournir une mise à jour sur les affaires. Le webcast sera accessible via la section Investisseurs du site web d'argenx, avec une rediffusion disponible pendant environ un an. L'entreprise a fourni des numéros d'accès internationaux pour la Belgique, la France, les Pays-Bas, le Royaume-Uni, les États-Unis, le Japon et la Suisse.
argenx (Euronext & Nasdaq: ARGX), ein globales Unternehmen im Bereich Immunologie, hat angekündigt, dass es am Donnerstag, den 31. Oktober 2024 um 13:30 Uhr MEZ (8:30 Uhr EST) eine Telefonkonferenz und einen Audio-Webcast abhalten wird, um die Finanzzahlen des dritten Quartals 2024 zu besprechen und ein Geschäftsupdate zu geben. Der Webcast wird über den Bereich Investoren der Website von argenx zugänglich sein, mit einer Wiederholung, die etwa ein Jahr lang verfügbar ist. Das Unternehmen hat internationale Einwahlnummern für Belgien, Frankreich, die Niederlande, das Vereinigte Königreich, die Vereinigten Staaten, Japan und die Schweiz bereitgestellt.
- None.
- None.
October 24, 2024
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, October 31, 2024 at 1:30 PM CET (8:30 AM ET) to discuss its third quarter 2024 financial results and provide a business update.
A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation.
Dial-in numbers:
Belgium 32 800 50 201
France 33 800 943355
Netherlands 31 20 795 1090
United Kingdom 44 800 358 0970
United States 1 888 415 4250
Japan 81 3 4578 9081
Switzerland 41 43 210 11 32
Use the access code 3810049 to join the call. Please dial in 15 minutes prior to the live call.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker in the U.S., Japan, Israel, the EU, the UK, Canada and China. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, X/Twitter, Instagram, Facebook, and YouTube.
For further information, please contact:
Media:
Ben Petok
bpetok@argenx.com
Investors:
Alexandra Roy (US)
aroy@argenx.com
Lynn Elton (EU)
lelton@argenx.com
FAQ
When will argenx (ARGX) report Q3 2024 earnings?
How can I access argenx (ARGX) Q3 2024 earnings call?
How long will argenx (ARGX) Q3 2024 earnings call replay be available?
